Status:
COMPLETED
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Rhode Island Hospital
Conditions:
Anxiety Disorders
Somatoform Disorders
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.
Detailed Description
We propose to conduct the first pharmacotherapy relapse prevention study in body dysmorphic disorder (BDD). BDD, an often-delusional preoccupation with a nonexistent or slight defect in appearance, is...
Eligibility Criteria
Inclusion
- Outpatient men and women age 18 and older
- Diagnosis of BDD within 6 months of study start date based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
- Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale
- Lives within driving distance of Boston, MA or Providence, RI
Exclusion
- Suicidal or homicidal tendencies
- Alcohol/drug abuse or dependence within 3 months of study entry
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00149799
Start Date
May 1 2005
End Date
March 1 2013
Last Update
December 5 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
2
Rhode Island Hospital
Providence, Rhode Island, United States, 02906